You are here

Global Spatiotemporal Disease Surveillance System

Award Information
Agency: Department of Defense
Branch: Office for Chemical and Biological Defense
Contract: W911NF-14-C-0077
Agency Tracking Number: C2-0384
Amount: $999,646.00
Phase: Phase II
Program: SBIR
Solicitation Topic Code: CBD13-102
Solicitation Number: 2013.1
Timeline
Solicitation Year: 2013
Award Year: 2014
Award Start Date (Proposal Award Date): 2015-05-18
Award End Date (Contract End Date): 2016-06-08
Small Business Information
10966 LE CONTE AVE
Los Angeles, CA 90024
United States
DUNS: 000000000
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 Onur Mudanyali
 Principal Scientist
 (310) 443-2070
 mudanyali@holomic.com
Business Contact
 Neven Karlovac
Title: CEO
Phone: (310) 443-2070
Email: nkarlovac@holomic.com
Research Institution
 Stub
Abstract

Rapid screening of chemical/biological threats and infectious diseases is a challenging task especially in remote locations due to the lack of appropriate laboratory infrastructure and advanced instrumentation. In such resource-scarce settings, wireless, robust, accurate, and easy-to-use diagnostics tools are required to enable real-time monitoring of various medical conditions, point-of-care applications and global disease surveillance. In this Phase II proposal, we aim to continue with the advanced development of a cell-phone based rapid diagnostic test reader platform and further enhance its hardware and software capabilities. In Phase I, feasibility of this cell-phone based spatiotemporal disease surveillance platform has been demonstrated, delivering a number of prototypes with encouraging system performance. Wirelessly integrated into remote database and servers, this platform enables digital quantitative evaluation of rapid diagnostic tests (lateral flow immuno-chromatographic assays) using a snap-on hardware attachment and software application on cell-phone devices. Phase II will provide opportunity for industrial level optimization, further performance improvements and fabrication of the platform toward advanced development and commercialization. As a result of fast progress during Phase I Holomic already commercialized a Pilot Reader in order to test the market and develop business relationship. Phase II will result in a @Clinic Reader for professional point-of-care applications and a @Home Reader for consumers and patient self monitoring. These readers are market-leading with performance, features, ease of use, and affordability.

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government